Plasmid encoding papillomavirus type 16 (HPV 16) DNA constructed with codon optimization improved the immunogenicity against HPV infection

Human papillomavirus Type 16 (HPV16) infections can cause neoplasia, which is thought to be closely associated with the development of cervical cancers. In the study, we attempted to construct a DNA plasmid encoding a HPV16 capsid protein (L1) and a RPV16 oncoprotein (E7), which was capable of preventing HPV16 infection and eliminating HPV 16-infected cells. A plasmid, LIE7hPSCA1. encoding the LI and E7 genes with the codon usage optimized for mammalian cell expression, was constructed. Mutations were introduced into the E! terre sequence for reducing its oncogenicity. C57BL/6 mice were intramuscularly immunized at tibialis anterior (TA) muscles with the newly constructed L1E7hpSCA1 plasmid. The immune responses induced by the LIE7hpSCA1 plasmid (with codon optimization) and a control L1E7pSCA1 plasmid (without codon optimization) were compared. It is shown that the L1E7hpSCA1 was able to induce much stronger immune responses than the L1E7pSCA1. Sera obtained from immunized animals were found to contain anti-HPV16 antibodies as detected by ELISA and hemagglutination inhibition (HAI) assays. Cytotoxicity and interferon-gamma assays showed that spleenocytes from immunized animals were able to recognize and lyze E7 expressing tumor TC-1 cells. Moreover, the growth of E7 expressing tumor mass inhibited in vaccinated mice. In vivo tumor protection test indicated that tumor formation was prevented in the experimental animals (6?%) after vaccination with L1E7hpSCA1. while for the control group injected with L1E7pSCA1 only and the animal group injected with pSCA1 only, tumor formation was observed in all experimental animals. Our results suggest that the L1E7h gene (with codon optimization) is Mow effective against HPV16 than the L1E7 gene(without codon optimization). The L1E7hpSCA1 plasmid was able to provide protection against E7 expressing tumor, and it might have the potential to be a vaccine candidate for HPV prevention. (C) 2004 Elsevier Ltd. All rights reserved.